slimvictor
Bluelight Crew
Teva has struck a new marketing agreement, and it’s one that’ll help the Israeli drugmaker blaze a new trail in the drug industry.
The pharma has inked a pact that will make it the only distributor in Israel of local company Syqe Medical’s cannabis inhaler, the companies said Monday, without disclosing any financial data on the agreement. Teva will also help Syqe set up a support and instruction team of nurses for patients and healthcare providers.
As of this year, Israel boasted about 26,000 medical cannabis consumption licenses—a figure that’s expected to double by 2018, Israeli newspaper Globes reports. And with licensed patients spending an average $100 per month on cannabis, the revenue potential is there for Teva if the company can get the inhaler selling.
cont at
http://www.fiercepharma.com/marketing/teva-inks-trailblazing-cannabis-pact-israel-s-syqe-medical
The pharma has inked a pact that will make it the only distributor in Israel of local company Syqe Medical’s cannabis inhaler, the companies said Monday, without disclosing any financial data on the agreement. Teva will also help Syqe set up a support and instruction team of nurses for patients and healthcare providers.
As of this year, Israel boasted about 26,000 medical cannabis consumption licenses—a figure that’s expected to double by 2018, Israeli newspaper Globes reports. And with licensed patients spending an average $100 per month on cannabis, the revenue potential is there for Teva if the company can get the inhaler selling.
cont at
http://www.fiercepharma.com/marketing/teva-inks-trailblazing-cannabis-pact-israel-s-syqe-medical
